EA202090489A1 - USE OF BUSPIRON FOR TREATMENT OF FUNCTIONAL HEADING - Google Patents

USE OF BUSPIRON FOR TREATMENT OF FUNCTIONAL HEADING

Info

Publication number
EA202090489A1
EA202090489A1 EA202090489A EA202090489A EA202090489A1 EA 202090489 A1 EA202090489 A1 EA 202090489A1 EA 202090489 A EA202090489 A EA 202090489A EA 202090489 A EA202090489 A EA 202090489A EA 202090489 A1 EA202090489 A1 EA 202090489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dizziness
treatment
functional
postural
buspiron
Prior art date
Application number
EA202090489A
Other languages
Russian (ru)
Inventor
Максим Валерьевич ЗАМЕРГРАД
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Publication of EA202090489A1 publication Critical patent/EA202090489A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины, фармакологии, а именно к новому применению буспирона или его фармацевтически приемлемой соли для лечения функционального головокружения, персистирующего постурального перцептивного головокружения (PPPD), постуральной фобической неустойчивости (PPV), хронического субъективного головокружения (CSD), эффект которого заключается в возможности лечения функционального головокружения, не зависящего от депрессивных и тревожных состояний, клинически оптимальной скорости наступления терапевтического эффекта, легкости титрования дозы, отсутствии седативного эффекта и благоприятном профиле безопасности.The invention relates to the field of medicine, pharmacology, namely to a new use of buspirone or its pharmaceutically acceptable salt for the treatment of functional dizziness, persistent postural perceptual dizziness (PPPD), postural phobic instability (PPV), chronic subjective dizziness (CSD), the effect of which is the possibility of treating functional dizziness independent of depressive and anxiety states, clinically optimal rate of onset of the therapeutic effect, ease of dose titration, lack of sedation, and a favorable safety profile.

EA202090489A 2017-08-15 2018-08-10 USE OF BUSPIRON FOR TREATMENT OF FUNCTIONAL HEADING EA202090489A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017129084A RU2660583C1 (en) 2017-08-15 2017-08-15 Use of buspirone for the treatment of functional dizziness
PCT/RU2018/000525 WO2019035741A1 (en) 2017-08-15 2018-08-10 Use of buspirone for treating functional dizziness

Publications (1)

Publication Number Publication Date
EA202090489A1 true EA202090489A1 (en) 2020-05-25

Family

ID=62816036

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090489A EA202090489A1 (en) 2017-08-15 2018-08-10 USE OF BUSPIRON FOR TREATMENT OF FUNCTIONAL HEADING

Country Status (6)

Country Link
KR (1) KR102407982B1 (en)
CN (1) CN111032048B (en)
BR (1) BR112020003227A2 (en)
EA (1) EA202090489A1 (en)
RU (1) RU2660583C1 (en)
WO (1) WO2019035741A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4634703A (en) 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
FR2763950B1 (en) * 1997-06-02 2002-09-20 Esteve Labor Dr 2- {4- [4- (4,5-DICHLORO-2-METHYLIMIDAZOL-1-YL) BUTYL] -1- PIPERAZINYL} -5-FLUOROPYRIMIDINE, ITS PREPARATION AND THERAPEUTIC USE
US6268368B1 (en) * 2000-03-01 2001-07-31 American Pharmaceuticals International Anionic exchange polymer complexes of buspirone
CA2607499C (en) * 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists

Also Published As

Publication number Publication date
BR112020003227A2 (en) 2021-03-23
WO2019035741A1 (en) 2019-02-21
CN111032048A (en) 2020-04-17
KR102407982B1 (en) 2022-06-14
RU2660583C1 (en) 2018-07-06
CN111032048B (en) 2023-04-04
KR20200038980A (en) 2020-04-14

Similar Documents

Publication Publication Date Title
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
PH12018502378A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
EA201691402A1 (en) PHARMACEUTICAL PREPARATION CONTAINING A COMPOUND OF THE PYRIDYLAMINOACIC ACID
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
EA202190395A1 (en) HETEROARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
NZ734635A (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
MY199237A (en) Methods of treating ocular conditions
EA201691570A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT
EA201692278A1 (en) FORMOTHEROL AND BUDESONIDE COMBINATION FOR THE TREATMENT OF COPD
EA202092719A1 (en) BENZENESULPHONAMIDE COMPOUNDS AND THEIR APPLICATION AS THERAPEUTIC AGENTS
EA202191548A1 (en) HUMAN PLASMA CALLICREIN INHIBITORS
JOP20200079A1 (en) Epidermal growth factor receptor inhibitors
PH12020551179A1 (en) Methods for treating mitochondrial disorder
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
IL304628A (en) Treatment of skin disorders
EA202090489A1 (en) USE OF BUSPIRON FOR TREATMENT OF FUNCTIONAL HEADING
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
EA201792170A1 (en) INDOLA DERIVATIVES
EA202190751A1 (en) METHODS FOR TREATMENT OF MYELOPROLIFERATIVE DISORDERS
EA202091523A1 (en) THERAPEUTIC AGENT FOR GLAUKOMA TREATMENT CONTAINING FP-RECEPTOR AGONIST AND -BLOCKER
EA201592058A1 (en) APPLICATION OF LANDIOLOL HYDROCHLORIDE IN LONG-TERM TREATMENT OF TACHIHARITHMIA